✦ LIBER ✦

Investigation of low 5-year relative survival for breast cancer in a London cancer network

✍ Scribed by Davies, E A; Linklater, K M; Coupland, V H; Renshaw, C; Toy, J; Park, R; Petit, J; Housden, C; Møller, H

Book ID: 110000643
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 233 KB
Volume: 103
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6605857

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cancer of the breast: 5-year survival in

Cancer of the breast: 5-year survival in a tertiary hospital in Uganda

✍ Gakwaya, A; Kigula-Mugambe, J B; Kavuma, A; Luwaga, A; Fualal, J; Jombwe, J; Gal 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 158 KB

Development of a prognostic nomogram for

Development of a prognostic nomogram for identifying those factors which influence the 2- and 5-year survival chances of Taiwanese women diagnosed with breast cancer

✍ Y-P. FAN; C-L. LIU; I-J. CHIANG; C-Y. LIN 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

An artificial neural network considerabl

An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: Results of a 5-year investigation

✍ Carsten Stephan; Klaus Jung; Henning Cammann; Birgit Vogel; Brigitte Brux; Glen 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 221 KB

## Abstract Our study was performed to evaluate the diagnostic usefulness of %fPSA alone and combined with an ANN at different PSA concentration ranges, including the low range 2–4 ng/ml, to improve the risk assessment of prostate cancer. A total of 928 men with prostate cancer and BPH without any

5-Year Results of Pulsed Dose Rate Brach

5-Year Results of Pulsed Dose Rate Brachytherapy Applied as a Boost after Breast-Conserving Therapy in Patients at High Risk for Local Recurrence from Breast Cancer

✍ Wolfgang Harms; Robert Krempien; Frank W. Hensley; Christiane Berns; Peter Fritz 📂 Article 📅 2002 🏛 Springer 🌐 German ⚖ 160 KB

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB